

May 03, 2024

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroze Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
--	---

Dear Sir/Madam,

**Sub: Completion of US FDA Inspection at Unit II of Eugia Pharma Specialities Ltd. (our wholly owned subsidiary) – Reg.,**

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected Unit-II, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Bhiwadi, Alwar, Rajasthan, from April 25<sup>th</sup> to May 3<sup>rd</sup> 2024.

The inspection closed with 7 observations. The observations are procedural in nature and will be responded to within the stipulated time.

We will keep the stock exchanges informed if there is any further information relating to the above in the future.

Please take the above information on record.

Thanking you,

Yours faithfully,  
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy  
Company Secretary

**AUROBINDO PHARMA LIMITED**  
[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)